• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Targeting FcRn for the modulation of antibody dynamics.靶向新生儿Fc受体(FcRn)以调节抗体动力学。
Mol Immunol. 2015 Oct;67(2 Pt A):131-41. doi: 10.1016/j.molimm.2015.02.007. Epub 2015 Mar 9.
2
Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?内体运输参数是否比 FcRn 结合亲和力更能成为改善单抗药代动力学的目标?
Mol Immunol. 2013 Dec;56(4):660-74. doi: 10.1016/j.molimm.2013.05.008. Epub 2013 Aug 2.
3
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.新生儿Fc受体(FcRn):治疗性抗体和抗体工程的新靶点。
J Drug Target. 2014 May;22(4):269-78. doi: 10.3109/1061186X.2013.875030. Epub 2014 Jan 9.
4
Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.基于同种细胞的新生儿 Fc 受体(FcRn)结合分析方法的鉴定及其在 IgG 类治疗药物 Fc 功能研究中的应用。
J Immunol Methods. 2013 Apr 30;390(1-2):81-91. doi: 10.1016/j.jim.2013.01.011. Epub 2013 Feb 4.
5
Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.第4章:通过利用细胞内转运功能进行多任务处理——FcRn的多种面貌
Adv Immunol. 2009;103:77-115. doi: 10.1016/S0065-2776(09)03004-1.
6
The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.非特异性结合、靶点介导的清除以及FcRn相互作用对人源化抗体药代动力学的影响。
MAbs. 2015;7(6):1084-93. doi: 10.1080/19420862.2015.1075109. Epub 2015 Sep 4.
7
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.新生儿Fc受体FcRn作为药物递送和治疗的靶点。
Adv Drug Deliv Rev. 2015 Aug 30;91:109-24. doi: 10.1016/j.addr.2015.02.005. Epub 2015 Feb 19.
8
Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.互补决定区的变化显著改变 IgG 与新生儿 Fc 受体(FcRn)的结合和药代动力学。
MAbs. 2018 Jan;10(1):81-94. doi: 10.1080/19420862.2017.1389355. Epub 2017 Nov 3.
9
A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K, K, endosome trafficking, and animal species.一个最小的基于生理学的药代动力学模型,用于研究 FcRn 介导的单克隆抗体回收:K 的影响、K、内体转运和动物物种。
MAbs. 2018 Nov-Dec;10(8):1322-1331. doi: 10.1080/19420862.2018.1506648. Epub 2018 Sep 11.
10
FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.新生儿Fc受体:从分子相互作用到IgG药代动力学及功能的调节
Curr Top Microbiol Immunol. 2014;382:249-72. doi: 10.1007/978-3-319-07911-0_12.

引用本文的文献

1
Long-Circulating Nanobody Confers Durable Prophylaxis against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection.长效循环纳米抗体赋予对严重急性呼吸综合征冠状病毒2奥密克戎感染的持久预防作用。
Adv Nanobiomed Res. 2025 Aug;5(8). doi: 10.1002/anbr.202400214. Epub 2025 Jun 27.
2
Considerations on the stability of IgG antibody in clinical specimens.关于临床样本中IgG抗体稳定性的考量
J Vet Diagn Invest. 2025 Jan;37(1):13-26. doi: 10.1177/10406387241296848. Epub 2024 Dec 14.
3
Rapid depletion of "catch-and-release" anti-ASGR1 antibody in vivo.体内“捕捉-释放”抗 ASGR1 抗体的快速耗竭。
MAbs. 2024 Jan-Dec;16(1):2383013. doi: 10.1080/19420862.2024.2383013. Epub 2024 Jul 25.
4
Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn.深入了解 IgG 与 FcRn 之间二价、pH 依赖性相互作用的亲合力-亲合力关系。
MAbs. 2024 Jan-Dec;16(1):2361585. doi: 10.1080/19420862.2024.2361585. Epub 2024 Jun 7.
5
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors.FMS 样酪氨酸激酶 3 激动剂 Fc 融合蛋白 GS-3583 治疗晚期实体瘤患者的 I 期研究。
Clin Cancer Res. 2024 Jul 15;30(14):2954-2963. doi: 10.1158/1078-0432.CCR-23-2808.
6
Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc.Fcγ 受体结合是 CD70-Fc 发挥最大免疫刺激作用所必需的。
Front Immunol. 2023 Oct 27;14:1252274. doi: 10.3389/fimmu.2023.1252274. eCollection 2023.
7
Comparative Molecular Characterization and Pharmacokinetics of IgG1-Fc and Engineered Fc Human Antibody Variants to Insulin-like Growth Factor 2 Receptor (IGF2R).比较胰岛素样生长因子 2 受体(IGF2R)的 IgG1-Fc 和工程化 Fc 人抗体变体的分子特征和药代动力学。
Molecules. 2023 Aug 3;28(15):5839. doi: 10.3390/molecules28155839.
8
Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.FcRn 抑制剂巴托昔单抗治疗甲状腺眼病的概念验证和随机、安慰剂对照试验。
J Clin Endocrinol Metab. 2023 Nov 17;108(12):3122-3134. doi: 10.1210/clinem/dgad381.
9
Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain.通过降低可变域的净正电荷,提高 HIV 中和 VRC01 类抗体的药代动力学。
MAbs. 2023 Jan-Dec;15(1):2223350. doi: 10.1080/19420862.2023.2223350.
10
Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?单克隆抗体作为长效产品:我们从人类免疫缺陷病毒(HIV)和 2019 冠状病毒病(COVID-19)中学到了什么?
Clin Infect Dis. 2022 Nov 21;75(Suppl 4):S530-S540. doi: 10.1093/cid/ciac751.

本文引用的文献

1
pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.pH 依赖性结合工程揭示了一个控制 IgG 循环的 FcRn 亲和力阈值。
J Biol Chem. 2015 Feb 13;290(7):4282-90. doi: 10.1074/jbc.M114.603712. Epub 2014 Dec 23.
2
Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.框架选择可以通过分子电荷的差异影响人源化治疗性抗体的药代动力学。
MAbs. 2014;6(5):1255-64. doi: 10.4161/mabs.29809. Epub 2014 Oct 30.
3
Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry.通过氢/氘交换质谱法研究新生儿Fc受体与单克隆抗体变体之间的相互作用。
Mol Cell Proteomics. 2015 Jan;14(1):148-61. doi: 10.1074/mcp.M114.042044. Epub 2014 Nov 6.
4
The Role of FcRn in Antigen Presentation.FcRn 在抗原呈递中的作用。
Front Immunol. 2014 Aug 27;5:408. doi: 10.3389/fimmu.2014.00408. eCollection 2014.
5
Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation.单个Fc甲硫氨酸氧化对FcRn结合的影响:Met252氧化比Met428氧化更显著地损害FcRn结合。
J Pharm Sci. 2015 Feb;104(2):368-77. doi: 10.1002/jps.24136. Epub 2014 Aug 29.
6
pH-dependent antigen-binding antibodies as a novel therapeutic modality.pH 依赖性抗原结合抗体作为一种新型治疗方式。
Biochim Biophys Acta. 2014 Nov;1844(11):1943-1950. doi: 10.1016/j.bbapap.2014.08.003. Epub 2014 Aug 12.
7
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.增强的新生儿Fc受体功能可改善对灵长类动物感染猴-人免疫缺陷病毒的保护作用。
Nature. 2014 Oct 30;514(7524):642-5. doi: 10.1038/nature13612. Epub 2014 Aug 13.
8
Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.人源FcRn转基因小鼠作为单克隆抗体药代动力学筛选工具的应用。
Xenobiotica. 2014 Dec;44(12):1127-34. doi: 10.3109/00498254.2014.941963. Epub 2014 Jul 17.
9
Application of FcRn binding assays to guide mAb development.应用FcRn结合测定法指导单克隆抗体的开发。
Drug Metab Dispos. 2014 Nov;42(11):1867-72. doi: 10.1124/dmd.114.059089. Epub 2014 Jul 14.
10
Use of Fc-Engineered Antibodies as Clearing Agents to Increase Contrast During PET.使用经Fc工程改造的抗体作为清除剂以增加正电子发射断层扫描(PET)期间的对比度。
J Nucl Med. 2014 Jul;55(7):1204-7. doi: 10.2967/jnumed.113.136481. Epub 2014 May 27.

靶向新生儿Fc受体(FcRn)以调节抗体动力学。

Targeting FcRn for the modulation of antibody dynamics.

作者信息

Ward E Sally, Devanaboyina Siva Charan, Ober Raimund J

机构信息

Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College Station, TX 77843-1114, USA; Department of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, College Station, TX 77843-1114, USA; Department of Immunology, University of Texas Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX 75390-9093, USA.

Department of Immunology, University of Texas Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX 75390-9093, USA.

出版信息

Mol Immunol. 2015 Oct;67(2 Pt A):131-41. doi: 10.1016/j.molimm.2015.02.007. Epub 2015 Mar 9.

DOI:10.1016/j.molimm.2015.02.007
PMID:25766596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4529761/
Abstract

The MHC class I-related receptor, FcRn, is a multitasking protein that transports its IgG ligand within and across cells of diverse origins. The role of this receptor as a global regulator of IgG homeostasis and transport, combined with knowledge of the molecular details of FcRn-IgG interactions, has led to opportunities to modulate the in vivo dynamics of antibodies and their antigens through protein engineering. Consequently, the generation of half-life extended antibodies has shown a rapid expansion over the past decade. Further, FcRn itself can be targeted by inhibitors to induce decreased levels of circulating IgGs, which could have applications in multiple clinical settings. The engineering of antibody-antigen interactions to reduce antibody-mediated buffering of soluble ligand has also developed into an active area of investigation, leading to novel antibody platforms designed to result in more effective antigen clearance. Similarly, the target-mediated elimination of antibodies by internalizing, membrane bound antigens (receptors) can be decreased using novel engineering approaches. These strategies, combined with subcellular trafficking analyses of antibody/antigen/FcRn behavior in cells to predict in vivo behavior, have considerable promise for the production of next generation therapeutics and diagnostics.

摘要

主要组织相容性复合体I类相关受体FcRn是一种多功能蛋白质,可在多种来源的细胞内及细胞间转运其IgG配体。该受体作为IgG稳态和转运的全局调节因子的作用,以及对FcRn-IgG相互作用分子细节的了解,为通过蛋白质工程调节抗体及其抗原的体内动力学创造了机会。因此,在过去十年中,半衰期延长抗体的产生迅速增加。此外,FcRn本身可被抑制剂靶向,以降低循环IgG的水平,这可能在多种临床环境中得到应用。通过工程改造抗体-抗原相互作用以减少抗体介导的可溶性配体缓冲作用,也已发展成为一个活跃的研究领域,催生了旨在实现更有效抗原清除的新型抗体平台。同样,使用新型工程方法可以减少内化的膜结合抗原(受体)对抗体的靶向介导清除。这些策略,结合对细胞内抗体/抗原/FcRn行为的亚细胞运输分析以预测体内行为,对于下一代治疗药物和诊断方法的生产具有相当大的前景。